Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6901 to 6915 of 8908 results

  1. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]

    In development Reference number: GID-TA11457 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

    Technology appraisal guidance
    Discontinued

  3. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

    Health technology evaluations
    In development

  4. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

    Health technology evaluations
    In development

  5. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Workplace health - older employees

    Discontinued Reference number: GID-PHG59

    NICE guideline
    Discontinued

  7. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development Reference number: GID-TA10858 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [ID6247]

    In development Reference number: GID-TA11251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A [ID6312]

    In development Reference number: GID-TA11329 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Gantenerumab for treating early Alzheimer's disease [ID6142]

    In development Reference number: GID-TA11269 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Transanal total mesorectal excision of the rectum (IPG514)

    This guidance has been updated and replaced by NICE HealthTech guidance 603.

    Withdrawn guidance

  13. Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure (IPG463)

    Interventional procedures, IPG463 - Issued: August 2013 --> This guidance has been updated and replaced by NICE HealthTech guidance 603.

    Withdrawn guidance

  14. Irreversible electroporation for treating prostate cancer (IPG768)

    We have moved interventional procedures guidance 768 to become HealthTech guidance 688. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (IPG805)

    We have moved interventional procedures guidance 805 to become HealthTech guidance 752. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance